Jonathan Weissman and team are out with a cancer-fighting biotech riding the appetite for those so-called “don’t eat me” and “eat me” signals.
The scientific co-founder — alongside fellow Whitehead Institute colleague Kipp Weiskopf and Stanford biologist Michael Bassik — has launched DEM BioPharma with incubator Longwood Fund and a crop of other investors.
In all, the nascent, 10-employee biotech has $70 million to bankroll hematology- and solid tumor-based programs, including a lead asset that could enter human trials in two to three years, CEO David Donabedian told Endpoints News.
Donabedian, a Longwood operating partner who has helmed the early stages of portfolio companies Axial Therapeutics and ImmuneID, is working with former Trillium Therapeutics CEO Jan Skvarka to set up shop and get the Cambridge, MA, startup rolling into new territory in the world of innate immune system checkpoints. The team came together earlier this year after Skvarka and crew…
Click here to view original post
Be the first to comment